August 2024 in “PLoS ONE” Younger Jordanians know more about rosemary, often using it for hair and stomach issues.
August 2024 in “Frontiers in Public Health” Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.
August 2024 in “Indian Journal of Skin Allergy” Stem-cell therapy shows promise for skin conditions but needs more research.
August 2024 in “Skin Research and Technology” PRP is an effective and safe treatment for female hair loss.
July 2024 in “Periodontology 2000” Autologous platelet concentrates show promise in esthetic treatments but need more standardized research.
Certain genes may influence hair loss differently in men and women.
July 2024 in “Journal of Cosmetic Dermatology” Vegan collagen builder improves hair growth, skin smoothness, and reduces wrinkles and pain.
June 2024 in “Skin Health and Disease” Men with alopecia often feel less confident and have lower wellbeing, needing more support.
June 2024 in “Computational and Structural Biotechnology Journal” Multi-omics techniques help understand the molecular causes of androgenetic alopecia.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
May 2024 in “Journal of cosmetic dermatology” "Dutasteride 0.5 mg daily is the most effective treatment for male hair loss."
May 2024 in “International journal of surgery case reports” A man had a large, rare cyst in his mouth removed after 10 years, which fixed his swallowing and breathing problems.
April 2024 in “Biomedicine & pharmacotherapy” Pilose antler extract helps hair grow in mice with a type of hair loss by speeding up the growth phase.
March 2024 in “International journal of pharmaceutics. X” Spanlastic-laden nanogel could be a better way to deliver hair growth medication through the skin for treating hair loss.
Meis2 is essential for touch sensation and nerve function in mice.
The transcription factor Meis2 is essential for touch sensation and proper nerve development in touch receptors.
February 2024 in “The Open dermatology journal” Alopecia Areata affects people of all ages worldwide, is likely caused by genetic and environmental factors, and can lead to stress and depression, highlighting the need for treatments that address both physical and mental health.
February 2024 in “Journal of Robotic Surgery” The document concludes that surgical robots improve surgery and recovery but are costly and can stress surgeons due to less patient contact.
February 2024 in “Advanced Science” The new scaffold with two growth factors speeds up skin healing and reduces scarring.
February 2024 in “BMC health services research” Policymakers should integrate criteria like risk of harm, skills, qualifications, and teamwork to define allied health professions in Malaysia.
January 2024 in “JEADV clinical practice” Gender-affirming dermatology treatments generally improve mental well-being for transgender individuals, but more research is needed.
January 2024 in “Medicine” Hypothyroidism is often linked to the hair loss condition telogen effluvium.
January 2024 in “Dermatologic Therapy” PRP therapy with specific growth factors improves hair density and thickness in androgenic alopecia.
December 2023 in “Trials” The trial is testing if a helmet that uses light can prevent hair loss during chemotherapy.
December 2023 in “Clinical, cosmetic and investigational dermatology” The new method combining dermoscopy and Reflectance Confocal Microscopy is more effective for evaluating vitiligo.
November 2023 in “Applied sciences” Pig blood can be used to mass-produce stable, low-cost platelet dry powder for medical use.
November 2023 in “ACS Omega” New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
Transplanted rat hair follicles grew hair and had increased but not fully restored nerve connections in mice.
Nanocarriers with plant extracts show promise for safe and effective hair growth treatment.
October 2023 in “F1000Research” TB lymphadenitis can occur in people with SLE on long-term immunosuppressive therapy.